The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

GSK GLAXOSMITHKLINE PLC ORD 25P




 Page 1 of 10

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Time/Date Code Headline Source Impact
07:00 15-Dec-2017 GSK Transfer of Shares out of Treasury RNS -0.53% Down
16:50 12-Dec-2017 GSK Director/PDMR Shareholding RNS +1.47% Up
16:16 12-Dec-2017 GSK GSK gains US approval for Nucala to treat EGPA RNS +1.47% Up
07:00 12-Dec-2017 GSK Promising data for GSK2857916 at ASH meeting RNS +1.47% Up
07:00 06-Dec-2017 GSK New data - Shingrix in immune-compromised patients RNS +0.19% Up
13:47 01-Dec-2017 GSK Director/PDMR Shareholding RNS -1.96% Down
13:44 01-Dec-2017 GSK Director/PDMR Shareholding RNS -1.96% Down
13:37 01-Dec-2017 GSK Total Voting Rights RNS -1.96% Down
07:00 30-Nov-2017 GSK ViiV starts Phase 3 HIV prevention study in women RNS -2.29% Down
14:03 27-Nov-2017 GSK ViiV starts Phase 3 longacting HIV treatment study RNS +0.18% Up
07:00 23-Nov-2017 GSK GSK submit IMPACT data to support Trelegy Ellipta RNS +0.34% Up
07:00 22-Nov-2017 GSK ViiV Juluca approved in US as first 2-drug regimen RNS +0.19% Up
14:21 21-Nov-2017 GSK GSK publishes 2018 dividend dates RNS -0.44% Down
07:00 16-Nov-2017 GSK Trelegy Ellipta EU approval for treatment of COPD RNS -0.86% Down
13:15 10-Nov-2017 GSK Director/PDMR Shareholding RNS -2.95% Down
17:00 09-Nov-2017 GSK Block listing Interim Review RNS -2.70% Down
14:00 08-Nov-2017 GSK Directorate Change RNS -1.73% Down
14:00 08-Nov-2017 GSK Directorate Change RNS -1.73% Down
15:01 07-Nov-2017 GSK US regulatory application for mepolizumab in COPD RNS -1.47% Down
07:35 02-Nov-2017 GSK BCMA receives FDA Breakthrough Therapy Designation RNS -0.62% Down

 Page 1 of 10

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.





Company Information
Updated Monthly
Company address C8 Gsk House, 980 Great West Road, Brentford, TW8 9GS, United Kingdom
Company website http://www.gsk.com
Market cap(in millions)* £ 63,680.75
Listing/Admission to trading 22 May 1972
Trading service SETS
Market Main Market
Listing category Premium Equity Commercial Companies
*The market capitalisation of companies reflects the London listed element only. These figures are approximate and are updated monthly.

Trading Information
16-Dec-17
FTSE index FTSE All-Share,FTSE Eurotop 300,FTSE 350 High Yield,FTSE 100,FTSE 350 (ex IT),FTSE techMARK All-Share,FTSE All-Share (ex IT),FTSE 350
FTSE sector Pharmaceuticals & Biotechnology
FTSE sub-sector Pharmaceuticals
Country of share register GB
Segment SET0
MiFID Status Regulated Market
Exchange market size 1,500
SEDOL 0925288
ISIN number GB0009252882



GLAXOSMITHKLINE share news analysis (GSK)